$BOLD News

Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Boundless Bio, Serapha Bio Ink All-Stock Merger Agreement; Combined Entity Anticipated To Trade On Nasdaq Under AATD Symbol

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Boundless Bio Q1 EPS $(0.60) Beats $(0.64) Estimate

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio Reveals Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio To Present Oral Kinesin Degrader Program At The AACR Annual Meeting 2026

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times